Advanced search
Publication Cover
OncoTargets and Therapy Volume 15, 2022 - Issue
Submit an article Journal homepage
216
Views
3
CrossRef citations to date
0
Altmetric
Case Series

Clinical Response to Neoadjuvant Immunotherapy Combined with Targeted Therapy and Chemotherapy in Oral Squamous Cell Carcinoma: Experience in Three Patients

Yu Tian1 Department of Stomatology, Medical School of Chinese PLA, Beijing, People’s Republic of China;2 Department of Stomatology, The First Medical Center, Chinese PLA General Hospital, Beijing, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-3847-4378
ORCID Icon,
Lei Zhang3 Department of Medicine, Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, People’s Republic of China
,
Nenghao Jin1 Department of Stomatology, Medical School of Chinese PLA, Beijing, People’s Republic of China;2 Department of Stomatology, The First Medical Center, Chinese PLA General Hospital, Beijing, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-7980-9723
ORCID Icon,
Zhiyi Wan3 Department of Medicine, Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, People’s Republic of China
,
Henghui Zhang4 Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, People’s Republic of China;5 Ninth School of Clinical Medicine, Peking University, Beijing, China; School of Oncology, Capital Medical University, Beijing, People’s Republic of China
,
Haizhong Zhang2 Department of Stomatology, The First Medical Center, Chinese PLA General Hospital, Beijing, People’s Republic of ChinaCorrespondence[email protected] [email protected]
&
Lei Zhang2 Department of Stomatology, The First Medical Center, Chinese PLA General Hospital, Beijing, People’s Republic of China
 show all
Pages 353-359 | Published online: 08 Apr 2022

References

  • Bamford J, Webster RM. The SCCHN drug market. Nat Rev Drug Discov. 2017;16(4):235–236. doi:10.1038/nrd.2016.261
  • Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, Phase 3 study. Lancet. 2019;394(10212):1915–1928. doi:10.1016/S0140-6736(19)32591-7
  • Xu MJ, Johnson DE, Grandis JR. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev. 2017;36(3):463–473. doi:10.1007/s10555-017-9687-8
  • Grau JJ, Caballero M, Verger E, Monzó M, Blanch JL. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol. 2009;129(11):1294–1299. doi:10.3109/00016480802590451
  • Olmos M, Glajzer J, Büntemeyer TO, et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma: case report and assessment of histological response. Front Oncol. 2021;11:720951. doi:10.3389/fonc.2021.720951
  • Pang X, Qian J, Jin H, et al. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency. J Immunother Cancer. 2020;8(2):e000463. doi:10.1136/jitc-2019-000463
  • Toki MI, Merritt CR, Wong PF, et al. High-plex predictive marker discovery for melanoma immunotherapy-treated patients using digital spatial profiling. Clin Cancer Res. 2019;25(18):5503–5512. doi:10.1158/1078-0432.CCR-19-0104
  • Liu Y, Zugazagoitia J, Ahmed FS, et al. Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. Clin Cancer Res. 2020;26(4):970–977. doi:10.1158/1078-0432.CCR-19-1040
  • Ahmed FS, Gaule P, McGuire J, et al. PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab with chemotherapy in triple-negative breast cancer. Clin Cancer Res. 2020;26(20):5456–5461. doi:10.1158/1078-0432.CCR-20-1303
  • Jiang C, Yuan F, Wang J, Wu L. Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages. Immunobiology. 2017;222(4):651–657. doi:10.1016/j.imbio.2016.12.002
  • Suárez-Sánchez FJ, Lequerica-Fernández P, Suárez-Canto J, et al. Macrophages in oral carcinomas: relationship with cancer stem cell markers and PD-L1 expression. Cancers. 2020;12(7):1764. doi:10.3390/cancers12071764
  • Stafford M, Kaczmar J. The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC. Cancers Head Neck. 2020;5(1):4. doi:10.1186/s41199-020-00052-8
  • Cabezas-Camarero S, Pérez-Segura P. Neoadjuvant immunotherapy in head and neck cancer: rationale, current evidence and future perspective. Crit Rev Oncol Hematol. 2022;169:103569. doi:10.1016/j.critrevonc.2021.103569
  • Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–443. doi:10.1158/2326-6066.CIR-15-0064

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.